This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FTCS
Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe
by Zacks Equity Research
Roche (RHHBY) obtains approval for Polivy in Europe for the treatment of adult patients with R/R DLBCL.
Top Stock Reports for Alphabet, JPMorgan & Comcast
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), JPMorgan Chase (JPM) and Comcast (CMCSA).
Should Value Investors Consider Amgen (AMGN) Stock Now?
by Zacks Equity Research
Let's see if Amgen (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.
Biogen Acquires Early-Stage CNS Drug From Pfizer for $75M
by Zacks Equity Research
Biogen (BIIB) signs deals with Pfizer to acquire rights to a CNS candidate and develop it as potential therapy to treat certain symptoms/disorders related to Alzheimer's disease and Parkinson's disease.
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - January 13, 2020
by Zacks Equity Research
Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.
Bet on Favorite Sector ETFs & Stocks This Earnings Season
by Sweta Killa
Like the first three quarters of 2019, the earnings picture looks weak for Q4 thanks to tough comparisons and moderating economic growth.
Merck's Keytruda Gets FDA Nod for High-Risk Bladder Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda gets FDA's approval to treat certain patients with high-risk, non-muscle invasive bladder cancer.
Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study
by Zacks Equity Research
Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.
Merck's Keytruda Misses One of Two Goals in Lung Cancer Study
by Zacks Equity Research
Merck's (MRK) phase III first-line SCLC study fails to meet one of the two primary endpoints. It signs an oncology collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals.
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen Stock Up in a Year on Pipeline & Biosimilar Progress
by Zacks Equity Research
Pipeline development and rapid progress in biosimilars program drive Amgen's (AMGN) stock 24% higher in the past year.
4 Reasons Why Investors Should Buy Alexion (ALXN) in 2020
by Zacks Equity Research
Alexion's (ALXN) growth prospects look strong for 2020 as Soliris maintains momentum and Ultomiris gains further traction.
Amgen (AMGN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Amgen (AMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
3 Investing Facts About Required Minimum Distributions You Need to Know - December 20, 2019
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU
by Zacks Equity Research
AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $241.94 in the latest trading session, marking a -0.37% move from the prior day.
Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More
by Zacks Equity Research
The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.
The Zacks Analyst Blog Highlights: Apple, Cisco Systems, Oracle, HSBC and Amgen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Cisco Systems, Oracle, HSBC and Amgen
Top Analyst Reports for Apple, Cisco & Oracle
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Cisco Systems (CSCO) and Oracle (ORCL).
Amarin Gains on FDA Approval of Vascepa Label Expansion
by Zacks Equity Research
Amarin (AMRN) gains as FDA approves a label expansion of Vascepa to reduce cardiovascular risk.
Amgen's Osteoporosis Drug Evenity Gets Approval in Europe
by Zacks Equity Research
The EC grants marketing authorization to Amgen (AMGN) and partner UCB's Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $234.01 in the latest trading session, marking a +0.07% move from the prior day.